Fundraising FoxPureTech Health — Full Portfolio
11 tracked investments · listed companies and verified rows first
Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.
BiotechHealthtechMenlo Park, US
Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in
BoardJonathan Silverstein(Director)inCarl Gordon(Director)inFlorent Gros(Director)
Co-investorsForesite CapitalOrbiMedPontifax Venture CapitalQuan CapitalaMoonNovartis Venture Fund
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO & Board Member)inSteven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)Michael Chen(Executive Officer)inLana Gladstein(Executive Officer)inAntony Loebel(Executive Officer)in
Co-investorsARCH Venture PartnersForesite CapitalGeneral AtlanticHAWKTAILSofinnova VenturesCPP Investments+3 more
Vor Biopharma is a biopharmaceutical company.
BiotechCambridge, US
Nathan Jorgensen(Executive Officer)Amy Mendel(Executive Officer)Robert Ang(Executive Officer, Director)Jean-Paul Kress(President, Chief Executive Officer and Chairman of the Board)in
BoardKush Parmar(Director)inJoshua Resnick(Director)
Co-investors5AM VenturesOUP (Osage University Partners)RA Capital
Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.
BiotechHealthtechMedical Devices
Co-investorsRA CapitalLeaps by Bayer
Chimera develops engineered cell therapies for cancer that produce therapeutic proteins only upon encountering tumor cells, using natural biological control mechanisms to improve safety and efficacy.
BiotechHealthtech
Co-investorsSand Hill AngelsShangBay Capital LLCWestern Technology Investment
Gelesis develops an oral superabsorbent hydrogel platform (OHS) built from naturally derived materials that works locally in the GI tract to influence satiety signals and support metabolic health.
BiotechDigital HealthHealthtechWellness & FitnessBoston, US
Yishai Zohar(Director, President, and Chief Executive Officer)inElliot Maltz(Treasurer)in
BoardJohn LaMattina(Director)Elon Boms(Director)inMeghan Fitzgerald(Director)Robert Forrester(Director)in
Co-investorsLaunchCapitalSalica InvestmentsCapstar VenturesInvescoOrbiMedVitruvian Partners
Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.
Co-investorsARCH Venture PartnersPivotal Life SciencesSofinnova VenturesAlexandriaWellcome Trust
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Akili Interactive LabsGallop OncologyKarunaKaruna Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.